Viatris Inc — Form 8-K
Filed November 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Viatris completed its acquisition of Pacira BioSciences on November 17, 2026, purchasing approximately 32.9 million shares (66.46% tendered) at $36.50 per share in cash, with the remaining shares acquired via merger at the same price. The deal values Pacira at approximately $1.2 billion. Pacira is expected to contribute $90–$100 million in revenues for the remaining 2026 (Nov 17–Dec 31). The acquisition aims to strengthen Viatris's U.S. innovative medicines business and establish leadership in non-opioid pain management.
Why this rating
Approximately 11.5% of company value; moderate strategic acquisition in growing pain-management segment. Real but not transformational relative to $10.4B market cap.
See more from November 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.